IBDEI11X ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18541,0)
 ;;=204.02^^102^1191^15
 ;;^UTILITY(U,$J,358.3,18541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18541,1,4,0)
 ;;=4^LYMPHOID LEUK AC,RELAPSE
 ;;^UTILITY(U,$J,358.3,18541,1,5,0)
 ;;=5^204.02
 ;;^UTILITY(U,$J,358.3,18541,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,18542,0)
 ;;=204.12^^102^1191^17
 ;;^UTILITY(U,$J,358.3,18542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18542,1,4,0)
 ;;=4^LYMPHOID LEUK CHR,RELAPSE
 ;;^UTILITY(U,$J,358.3,18542,1,5,0)
 ;;=5^204.12
 ;;^UTILITY(U,$J,358.3,18542,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,18543,0)
 ;;=204.11^^102^1191^18
 ;;^UTILITY(U,$J,358.3,18543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18543,1,4,0)
 ;;=4^LYMPHOID LEUK CHR,REMISSION
 ;;^UTILITY(U,$J,358.3,18543,1,5,0)
 ;;=5^204.11
 ;;^UTILITY(U,$J,358.3,18543,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,18544,0)
 ;;=204.22^^102^1191^19
 ;;^UTILITY(U,$J,358.3,18544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18544,1,4,0)
 ;;=4^LYMPHOID LEUK SUBACUTE,RELAPSE
 ;;^UTILITY(U,$J,358.3,18544,1,5,0)
 ;;=5^204.22
 ;;^UTILITY(U,$J,358.3,18544,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,18545,0)
 ;;=204.21^^102^1191^20
 ;;^UTILITY(U,$J,358.3,18545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18545,1,4,0)
 ;;=4^LYMPHOID LEUK SUBACUTE,REMISS
 ;;^UTILITY(U,$J,358.3,18545,1,5,0)
 ;;=5^204.21
 ;;^UTILITY(U,$J,358.3,18545,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,18546,0)
 ;;=200.18^^102^1191^21
 ;;^UTILITY(U,$J,358.3,18546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18546,1,4,0)
 ;;=4^LYMPHOSARC,LYMPH NODE MULTI
 ;;^UTILITY(U,$J,358.3,18546,1,5,0)
 ;;=5^200.18
 ;;^UTILITY(U,$J,358.3,18546,2)
 ;;=^267357
 ;;^UTILITY(U,$J,358.3,18547,0)
 ;;=202.38^^102^1191^22
 ;;^UTILITY(U,$J,358.3,18547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18547,1,4,0)
 ;;=4^MAL HISTIOCYTOSIS NODES MULTI
 ;;^UTILITY(U,$J,358.3,18547,1,5,0)
 ;;=5^202.38
 ;;^UTILITY(U,$J,358.3,18547,2)
 ;;=^267471
 ;;^UTILITY(U,$J,358.3,18548,0)
 ;;=202.88^^102^1191^23
 ;;^UTILITY(U,$J,358.3,18548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18548,1,4,0)
 ;;=4^MAL LYMPHOMAS,OTH
 ;;^UTILITY(U,$J,358.3,18548,1,5,0)
 ;;=5^202.88
 ;;^UTILITY(U,$J,358.3,18548,2)
 ;;=^267503
 ;;^UTILITY(U,$J,358.3,18549,0)
 ;;=202.68^^102^1191^24
 ;;^UTILITY(U,$J,358.3,18549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18549,1,4,0)
 ;;=4^MAL MAST CELL TUMORS LYMPH
 ;;^UTILITY(U,$J,358.3,18549,1,5,0)
 ;;=5^202.68
 ;;^UTILITY(U,$J,358.3,18549,2)
 ;;=^267495
 ;;^UTILITY(U,$J,358.3,18550,0)
 ;;=200.48^^102^1191^25
 ;;^UTILITY(U,$J,358.3,18550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18550,1,4,0)
 ;;=4^MANTLE CELL LYMPH MULTIP
 ;;^UTILITY(U,$J,358.3,18550,1,5,0)
 ;;=5^200.48
 ;;^UTILITY(U,$J,358.3,18550,2)
 ;;=^335204
 ;;^UTILITY(U,$J,358.3,18551,0)
 ;;=200.38^^102^1191^26
 ;;^UTILITY(U,$J,358.3,18551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18551,1,4,0)
 ;;=4^MARGIN ZONE LYMPH MULTIP
 ;;^UTILITY(U,$J,358.3,18551,1,5,0)
 ;;=5^200.38
 ;;^UTILITY(U,$J,358.3,18551,2)
 ;;=^335196
 ;;^UTILITY(U,$J,358.3,18552,0)
 ;;=206.01^^102^1191^30
 ;;^UTILITY(U,$J,358.3,18552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18552,1,4,0)
 ;;=4^MONOCYTIC LEUK AC,REMISSION
 ;;^UTILITY(U,$J,358.3,18552,1,5,0)
 ;;=5^206.01
 ;;^UTILITY(U,$J,358.3,18552,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,18553,0)
 ;;=206.02^^102^1191^29
 ;;^UTILITY(U,$J,358.3,18553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18553,1,4,0)
 ;;=4^MONOCYTIC LEUK AC,RELAPSE
 ;;^UTILITY(U,$J,358.3,18553,1,5,0)
 ;;=5^206.02
 ;;^UTILITY(U,$J,358.3,18553,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,18554,0)
 ;;=206.12^^102^1191^31
 ;;^UTILITY(U,$J,358.3,18554,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI11X
